Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : The agreement aims to discover and develop drug candidates targeting two different ion channel targets associated with neurological disorders. Autifony will lead drug discovery and preclinical development activities on the two targets.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 14, 2023
Lead Product(s) : AUT00206
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase I
Sponsor : Boehringer Ingelheim GmbH
Deal Size : $50.1 million
Deal Type : Termination
Autifony Therapeutics Regains Rights to Clinical Stage Kv3 Programme
Details : Boehringer Ingelheim will not be exercising its Option under the Option for Asset Purchase Agreement which was signed by the two companies in December 2017. Autifony has regained full rights to its Kv3 programme.
Product Name : AUT00206
Product Type : Other Small Molecule
Upfront Cash : $29.5 million
August 26, 2020
Lead Product(s) : AUT00206
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase I
Sponsor : Boehringer Ingelheim GmbH
Deal Size : $50.1 million
Deal Type : Termination
Reset All
